12:00 AM
 | 
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Glybera alipogene tiparvovec regulatory update

The European Commission approved Glybera alipogene tiparvovec from uniQure to treat lipoprotein lipase (LPL) deficiency in patients with recurring, acute pancreatitis. Glybera is the first gene therapy approved by regulatory authorities outside of China. uniQure plans to launch Glybera in Europe in 2H13 starting in Germany. The company said it first has to scale...

Read the full 259 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >